Characterization of Nucleoside Reverse Transcriptase Inhibitor-Associated Mutations in the RNase H Region of HIV-1 Subtype C Infected Individuals

The South African national treatment programme includes nucleoside reverse transcriptase inhibitors (NRTIs) in both first and second line highly active antiretroviral therapy regimens. Mutations in the RNase H domain have been associated with resistance to NRTIs but primarily in HIV-1 subtype B studies. Here, we investigated the prevalence and association of RNase H mutations with NRTI resistance in sequences from HIV-1 subtype C infected individuals. RNase H sequences from 112 NRTI treated but virologically failing individuals and 28 antiretroviral therapy (ART)-naive individuals were generated and analysed. In addition, sequences from 359 subtype C ART-naive sequences were downloaded from Los Alamos database to give a total of 387 sequences from ART-naive individuals for the analysis. Fisher's exact test was used to identify mutations and Bayesian network learning was applied to identify novel NRTI resistance mutation pathways in RNase H domain. The mutations A435L, S468A, T470S, L484I, A508S, Q509L, L517I, Q524E and E529D were more prevalent in sequences from treatment-experienced compared to antiretroviral treatment naive individuals, however, only the E529D mutation remained significant after correction for multiple comparison. Our findings suggest a potential interaction between E529D and NRTI-treatment; however, site-directed mutagenesis is needed to understand the impact of this RNase H mutation.

[1]  T. Silander,et al.  Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[2]  A. Nowé,et al.  Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. , 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[3]  N. Sluis-Cremer,et al.  Mutational Analysis of Tyr-501 of HIV-1 Reverse Transcriptase , 2002, The Journal of Biological Chemistry.

[4]  G. Shaw,et al.  Molecular cloning and characterization of the HTLV-III virus associated with AIDS , 1984, Nature.

[5]  S. Iordanskiy,et al.  Subtype-associated differences in HIV-1 reverse transcription affect the viral replication , 2010, Retrovirology.

[6]  V. Calvez,et al.  Relationship between mutations in HIV‐1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre‐treated HIV infected patients , 2007, Journal of medical virology.

[7]  O. Gascuel,et al.  New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. , 2010, Systematic biology.

[8]  M. Parniak,et al.  Virion Instability of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Mutated in the Protease Cleavage Site between RT p51 and the RT RNase H Domain , 2005, Journal of Virology.

[9]  V. Pathak,et al.  Mutations in Human Immunodeficiency Virus Type 1 RNase H Primer Grip Enhance 3′-Azido-3′-Deoxythymidine Resistance , 2007, Journal of Virology.

[10]  S. Sarafianos,et al.  Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients. , 2009, Antiviral Research.

[11]  Tulio de Oliveira,et al.  A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences , 2009, Nucleic Acids Res..

[12]  V. Pathak,et al.  Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Increase Resistance to 3′-Azido-3′-Dideoxythymidine , 2007, Journal of Virology.

[13]  Anne-Mieke Vandamme,et al.  Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[14]  Yunus Moosa,et al.  Adult antiretroviral therapy guidelines 2017 , 2017, Southern African journal of HIV medicine.

[15]  S. Hammer,et al.  The challenge of HIV-1 subtype diversity. , 2008, The New England journal of medicine.

[16]  P. Ghys,et al.  Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004 , 2006, AIDS.

[17]  M. Soares,et al.  Identification of Novel Resistance-Related Polymorphisms in HIV-1 Subtype C RT Connection and RNase H Domains from Patients Under Virological Failure in Brazil. , 2016, AIDS research and human retroviruses.

[18]  M. Wainberg,et al.  Variations in Reverse Transcriptase and RNase H Domain Mutations in Human Immunodeficiency Virus Type 1 Clinical Isolates Are Associated with Divergent Phenotypic Resistance to Zidovudine , 2007, Antimicrobial Agents and Chemotherapy.

[19]  Lynn Morris,et al.  HIV-1 pol mutation frequency by subtype and treatment experience: extension of the HIVseq program to seven non-B subtypes , 2006, AIDS.

[20]  M. Wainberg,et al.  Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996–2008) , 2009, Journal of the International AIDS Society.

[21]  B. Walker,et al.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. D. Clark,et al.  Crystal structure of HIV‐1 reverse transcriptase in complex with a polypurine tract RNA:DNA , 2001, The EMBO journal.

[23]  P. Libin,et al.  Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine. , 2010, The Journal of general virology.

[24]  M. Soares,et al.  Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations. , 2011, The Journal of antimicrobial chemotherapy.

[25]  K. Moelling,et al.  Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo- and endonuclease activities. , 1991, Journal of molecular biology.

[26]  Emma B. Saxon.  Multiple comparisons , 2015, BMC Biology.

[27]  M. Soares,et al.  Conservation Patterns of HIV-1 RT Connection and RNase H Domains: Identification of New Mutations in NRTI-Treated Patients , 2008, PloS one.

[28]  V. Pathak,et al.  Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  V. Pathak,et al.  Mutations in the connection domain of HIV-1 reverse transcriptase increase 3′-azido-3′-deoxythymidine resistance , 2007, Proceedings of the National Academy of Sciences.

[30]  S. Sarafianos,et al.  Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Ndung’u,et al.  Drug resistance and coreceptor usage in HIV type 1 subtype C-infected children initiating or failing highly active antiretroviral therapy in South Africa. , 2012, AIDS research and human retroviruses.

[32]  B. Larder,et al.  Mutations within the RNase H domain of human immunodeficiency virus type 1 reverse transcriptase abolish virus infectivity. , 1991, The Journal of general virology.

[33]  K. White,et al.  Mutations in the thumb–connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients , 2009, Antiviral therapy.

[34]  K. Moelling,et al.  Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H. , 1993, The Journal of biological chemistry.